Contact a Product Expert

SSO₂ Therapy is the only FDA-approved treatment to reduce infarct size following STEMI. SSO₂ utilizes proprietary technology to deliver hyperoxemic blood locally to the patient's coronary artery following primary PCI.

Please fill out the form and a product expert on SSO₂ Therapy will be in touch to address your questions.